Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 59, Issue 1, 2004, Pages 78-86

  Bradley, Jeffrey ^a,b,c   Thorstad, Wade L ^a,b   Mutic, Sasa ^a   Miller, Tom R ^a,b   Dehdashti, Farrokh ^a,b   Siegel, Barry A ^a,b   Bosch, Walter ^a   Bertrand, Rudi J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

FDG PET; Non small cell lung cancer; Radiation therapy; Target delineation

Indexed keywords

CELLS; COMPUTER SIMULATION; COMPUTERIZED TOMOGRAPHY; GLUCOSE; PATIENT MONITORING; PULMONARY DISEASES; RADIOTHERAPY; TUMORS;

CONFORMAL RADIATION; LASER POSITIONING; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY (PET);

ONCOLOGY;

FLUORODEOXYGLUCOSE F 18;

ARTICLE; ATELECTASIS; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIOLOGIST; SIMULATION; TREATMENT PLANNING; TUMOR VOLUME;

ATELECTASIS; CARCINOMA, NON-SMALL-CELL LUNG; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PILOT PROJECTS; PROSPECTIVE STUDIES; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 4444289151     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.10.044     Document Type: Article

References (26)

1. Zhang H.X., Yin W.B., Zhang L.J., et al. Curative radiotherapy of early operable non-small cell lung cancer. Radiother Oncol. 14:1989;89-94.
2. Kaskowitz L., Graham M.V., Emami B., et al. Radiation therapy alone for Stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 27:1993;517-523.
3. Dillman R.O., Herndon J., Seagren S.L., et al. Improved survival in stage III non-small-cell lung cancer: Seven year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst. 88:1996;1210-1215.
4. Sibley G.S., Jamieson T.A., Marks L.B., et al. Radiotherapy alone for medically inoperable stage I non-small cell lung cancer: The Duke experience. Int J Radiat Oncol Biol Phys. 40:1998;149-154.
5. Furuse K., Fukuoka M., Kawahara M., et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol. 17:1999;2692-2699.
6. Bradley J.D., Wahab S., Lockett M.A., et al. Elective nodal failures are uncommon in medically inoperable patients with Stage I non-small-cell lung carcinoma treated with limited radiotherapy fields. Int J Radiat Oncol Biol Phys. 56:2003;342-347.
7. Arriagada R., Le Chevalier T., Quoix E., et al. Effect of chemotherapy on locally advanced non-small cell lung carcinoma: A randomized study of 353 patients. Int J Radiat Oncol Biol Phys. 20:1991;1183-1190.
8. LeChevalier T., Brisgand D., Douillard J.Y. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol. 12:1994;360-367.
9. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: A review of the current evidence. Chest 2003;123:137S-146.
10. Perez C., Bradley J., Chao C., et al. Functional imaging in treatment planning in radiation therapy: A review. Rays. 27:2002;157-173.
11. Lewis P., Griffin S., Marsden P. Whole-body 18F-fluorodeoxyglucose positron emossion tomography in preoperative evaluation of lung cancer. Lancet. 344:1994;1265-1266.
12. Valk P.E., Pounds T.R., Hopkins D.M., et al. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging. Ann Thorac Surg. 60:1995;1573-1582.
13. Weder W, Schmid R, Bruchhaus H. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998;886-893.
14. MacManus M.P., Hicks R.J., Ball D.L., et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: Powerful correlation with survival and high impact on treatment. Cancer. 92:2001;886-895.
15. Kiffer J., Berlangieri S., Scott A., et al. The contribution of 18F-fluro-seoxyglucose positron emission tomography imaging to radiotherapy planning in lung cancer. Lung Cancer. 19:1998;167-177.
16. Munley M.T., Marks L.B., Scarfone C., et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: Challenges and prospects. Lung Cancer. 23:1999;105-114.
17. Nestle U., Walter K., Schmidt S., et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 44:1999;593-597.
18. Vanuystel L., Vansteenkiste J., Sroobants S., et al. The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 55:2000;317-324.
19. Giraud P., Grahek D., Montravers F., et al. CT and 18F-deoxyglucose (FDG) image fusion or optimization on conformal radiotherapy in lung cancers. Int J Radiat Oncol Biol Phys. 49:2001;1249-1257.
20. Erdi Y., Rosenzweig K., Erdi A., et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 62:2002;51-60.
21. Mah K., Caldwell C., Ung Y., et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys. 52:2002;339-350.
22. Miller T., Grigsby P. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys. 53:2002;353-359.
23. Kwa S.L.S., Lebesque J.V., Theuws J.C.M., et al. Radiation pneumonitis as a function of mean dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys. 42:1998;1-9.
24. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 45:1999;323-329.
25. Singh A.K., Lockett M.A., Bradley J.D. Predictors of radiation-induced esophageal toxicity in patients with non-small cell lung cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 55:2001;337-341.
26. Lardinois D., Weder W., Hany T.F., et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 348:2003;2500-2507.